| Literature DB >> 30115051 |
Krista R Wooller1,2,3, Chantal Backman4,5, Shipa Gupta6, Alison Jennings7, Delvina Hasimja-Saraqini8,5,9, Alan J Forster10,6,11.
Abstract
BACKGROUND: Urinary catheters are a common medical intervention, yet they can also be associated with harmful adverse events such as infection, urinary tract trauma, delirium and patient discomfort. The purpose of this study was to describe the use of the SafetyLEAP program to drive improvement efforts, and specifically to reduce the use of urinary catheters on general internal medicine wards.Entities:
Keywords: Patient safety; Quality improvement; Urinary catheter
Mesh:
Year: 2018 PMID: 30115051 PMCID: PMC6097441 DOI: 10.1186/s12913-018-3421-2
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Timeline of SafetyLEAP intervention
Adherence with program
| Activity | POINTS | |
|---|---|---|
| Yes = 1, Partial = 0.5, No = 0 | ||
| GIM ward #1 | GIM ward #2 | |
| ENGAGEMENT | 100.00% | 100.00% |
| Leadership support | 1 | 1 |
| Local champion | 1 | 1 |
| Other key project members | 1 | 1 |
| Communication plan | 1 | 1 |
| Resources provided | 1 | 1 |
| AUDIT AND FEEDBACK | 92.9% | 92.9% |
| Audit and feedback training | 1 | 1 |
| Audit triggers confirmed | 1 | 1 |
| Case findings | 1 | 1 |
| Case reviews | 1 | 1 |
| Composition of multidisciplinary review team | 0.5 | 0.5 |
| Results summarized (including case classification) | 1 | 1 |
| Results reviewed | 1 | 1 |
| QUALITY IMPROVEMENT | 100.00% | 100.00% |
| Plan - Priority selected | 1 | 1 |
| Plan - Local QI team identified | 1 | 1 |
| Plan - Plan to test the change documented | 1 | 1 |
| Do - Plan implemented | 1 | 1 |
| Study - Results monitored | 1 | 1 |
| Act - Results summarized | 1 | 1 |
| Act - Decision taken on next steps | 1 | 1 |
| FULL PROGRAM | 97.4% | 97.4% |
Patient characteristics during audit and feedback
| Variable | Ward # 1 | Ward # 2 | All Sites |
|---|---|---|---|
| Patient encounters, N | 298 | 263 | 561 |
| Unique Patients Observed, N | 283 | 252 | 534a |
| Female, N (%) | 160 (53.7%) | 131 (49.8%) | 291 (51.9%) |
| Patient Age, mean (median) | 71.5 (76) | 66.5 (69) | 69.1 (73) |
| Days Observed per Encounter, average (median) | 9.6 (7) | 8.6 (6) | 9.1 (6) |
| Admitting diagnoses (10 most common) | |||
| Pneumonia | 27 (9.1%) | 34 (12.9%) | 61 (10.9%) |
| Congestive Heart Failure | 13 (4.4%) | 16 (6.1%) | 29 (5.2%) |
| COPD exacerbation | 19 (6.4%) | 4 (1.5%) | 23 (4.1%) |
| Sepsis | 15 (5.0%) | 6 (2.3%) | 21 (3.7%) |
| Cellulitis | 11 (3.7%) | 9 (3.4%) | 20 (3.6%) |
| Failure to cope | 8 (2.7%) | 11 (4.2%) | 19 (3.4%) |
| Acute Renal Failure | 7 (2.3%) | 9 (3.4%) | 16 (2.9%) |
| Delirium | 6 (2.0%) | 9 (3.4%) | 15 (2.7%) |
| GI bleed (Upper) | 10 (3.4%) | 5 (1.9%) | 15 (2.7%) |
| Weakness | 9 (3.0%) | 4 (1.5%) | 13 (2.3%) |
| Comorbidities (10 most common) | |||
| Hypertension | 154 (51.7%) | 109 (41.4%) | 263 (46.9%) |
| Diabetes Mellitus Type 2 | 76 (25.5%) | 68 (25.9%) | 144 (25.7%) |
| Atrial Fibrillation | 68 (22.8%) | 40 (15.2%) | 108 (19.3%) |
| Congestive Heart Failure | 55 (18.5%) | 34 (12.9%) | 89 (15.9%) |
| Chronic Obstructive Pulmonary Disease | 53 (17.8%) | 36 (13.7%) | 89 (15.9%) |
| Chronic Kidney Disease | 44 (14.8%) | 33 (12.5%) | 77 (13.7%) |
| Dyslipidemia | 33 (11.1%) | 37 (14.1%) | 70 (12.5%) |
| Gastroesophageal Reflux Disease | 30 (10.1%) | 33 (12.5%) | 63 (11.2%) |
| Hypothyroidism | 32 (10.7%) | 29 (11.0%) | 61 (10.9%) |
| Dementia | 29 (9.7%) | 28 (10.6%) | 57 (10.2%) |
aNote: One patient was observed at both campuses. 12 encounters do not have comorbidities entered
Catheter associated adverse events during audit and feedback – classification
| WHO Level 1 Classification | Total Events* | Urinary catheter events* | Preventable AE* | Non-Preventable AE* | Potential AE* |
|---|---|---|---|---|---|
| Clinical process/procedure | 148 (49.5%) | 14 (70%) | 8 (61.5%) | 3 (75%) | 3 (100%) |
| Healthcare associated infection | 28 (9.4%) | 5 (25%) | 5 (38.5%) | 0 (0%) | 0 (0%) |
| Medication/IV fluid/biological (includes vaccine) | 79 (26.4%) | 1 (5%) | 0 (0%) | 1 (25%) | 0 (0%) |
| Other | 44 (14.7%) | 0 | – | – | – |
| Total | 299 (100%) | 20 (100%) | 13 (100%) | 4 (100%) | 3 (100%) |
*Percentages are relative to column totals
Fig. 2Urinary catheter protocol
Patient characteristics during quality improvement intervention
| Pre-intervention (N = 824) | Post-interventions (N = 777) |
| |
|---|---|---|---|
| Female, N(%) | 415 (50.4) | 417 (53.7) | |
| Ward 1, N(%) | 388 (47.1) | 371 (47.8) | |
| Age, mean (median, IQR) | 73.0 (74, 61–85) | 72.6 (75,58–85) | |
| Length of stay, mean (median) | 7.0 days (7) | 6.6 days (6) |
Fig. 3Run chart of urinary catheter point prevalence during planned quality improvement
Catheter Utilization Ratio, Unnecessary Catheter Utilization Ratio, CAUTI and CA-ASB before and after catheter protocol introduction
| Pre-intervention (N = 824) | Post-intervention (N = 777) | |||
|---|---|---|---|---|
| Catheter days | 952 | 716 | ||
| Patient days | 6617 | 6167 | ||
| Catheter Utilization Ratio | 0.144 | 0.116 | ||
| Unnecessary Catheter Utilization % | 35.0 | 26.7 | ||
| CAUTI rate – incident CAUTI per 1000 catheter-days (N) | 21 (20) | 24 (17) | Rate ratio 1.13 (95% CI 0.56–2.3) | |
| CA-ASB rate – incident CA-ASB per 1000 catheter-days (N) | 20 (19) | 9.8 (7) | Rate ratio 0.49 (95% CI 0.17–1.2) | |
| CAUTI rate with appropriate antibiotics (N) | 19 (18) | 22.3(16) | Rate ratio 1.18 (95% CI 0.56–2.4) | |
| CA-ASB rate treated with antibiotics (N) | 14.7 (14) | 2.8 (2) | Rate ratio 0.19 (95% CI 0.02–0.83) | |